Barclays upgrades CVS Health to Overweight, citing gains in pharmacy market share and potential upside from CostVantage. CVS is expected to recover 200 basis points in Medicare margins by 2026, ...

Key Takeaways A higher-than-anticipated report on consumer inflation sent U.S. equities lower at midday.Solar power company ...

CVS Health, one of the biggest players in the battle to acquire physicians, is facing a possible split amid major financial struggles. In 2023, CVS Health spent $10.6 billion to acquire primary care ...

Analysts upgraded shares of the healthcare company to Overweight from Equal Weight and raised their price target to $82.

CVS Health (CVS) stock gained as Barclays upgraded the company, citing a compelling path to margin recovery in its Medicare ...

CVS Health (CVS – Research Report) received a Buy rating and an $82.00 price target from Barclays analyst Andrew Mok CFA today. The ...